Skip to main content
رجوع
CRVS logo

Corvus Pharmaceuticals, Inc.

جودة البيانات: 100%
ذروة بيع
CRVS
NASDAQ Healthcare Biotechnology
KWD 13.15
▼ KWD 0.60 (-4.36%)
القيمة السوقية: 1.10B
نطاق اليوم
KWD 12.99 KWD 13.82
نطاق 52 أسبوعًا
KWD 2.54 KWD 26.95
حجم التداول
1,179,540
متوسط 50 يوم / 200 يوم
KWD 16.97 / KWD 8.91
الإغلاق السابق
KWD 13.75

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E -72.3 0.3
P/B 18.1 2.9
ROE % -32.6 3.7
Net Margin % 3.8
Rev Growth 5Y % 10.0
D/E 0.0 0.2

السعر المستهدف للمحللين

Hold
KWD 31.800 +141.8%
Low: KWD 27.000 High: KWD 42.000
ربحية السهم المستقبلية
-KWD 0.694
الإيرادات المقدّرة
1.2 M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 0.118
KWD 0.098 – KWD 0.138
240 M 2
FY2029 -KWD 0.456
-KWD 0.535 – -KWD 0.377
130 M 4
FY2028 -KWD 0.636
-KWD 1.559 – KWD 0.051
58 M 6

النقاط الرئيسية

Debt/Equity of 0.02 — conservative balance sheet
Negative free cash flow of -32.97M
PEG of 0.49 suggests growth is underpriced

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-32.60%
ROIC-51.86%
Net MarginN/A
Op. MarginN/A

الأمان

Debt / Equity
0.02
Current Ratio6.21
Interest Coverage0.00

التقييم

P/E Ratio
-72.27
P/B Ratio18.05
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0.0 Net Income (TTM) -15.28M
ROE -32.60% ROA -21.49%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -32.97M
ROIC -51.86% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.02 Current Ratio 6.21
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -72.27 P/B Ratio 18.05
P/S Ratio N/A PEG Ratio 0.49
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 1.10B Enterprise Value 1.10B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0.0 0.0 0.0 0.0 0.0
Net Income -15.28M -62.29M -27.03M -41.31M -43.24M
EPS (Diluted) -0.53 -1.02 -0.56 -0.89 -1.03
Gross Profit -105,000.0 0.0 0.0 0.0 0.0
Operating Income -42.97M -27.55M -23.41M -32.57M -38.63M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 71.12M 68.91M 45.55M 68.24M 109.46M
Total Liabilities 9.91M 36.34M 6.87M 12.13M 12.29M
Shareholders' Equity 61.21M 32.57M 38.68M 56.12M 97.16M
Total Debt 937,000.0 1.12M 1.37M 2.60M 3.65M
Cash & Equivalents 4.58M 8.74M 12.62M 13.16M 63.46M
Current Assets 58.21M 54.41M 27.96M 43.66M 71.31M
Current Liabilities 9.38M 35.40M 6.87M 10.75M 9.69M